CRISPR Therapeutics AG (NASDAQ:CRSP) has a beta value of 1.75 and has seen 0.95 million shares traded in the recent trading session. The company, currently valued at $5.20B, closed the recent trade at $61.72 per share which meant it lost -$3.47 on the day or -5.32% during that session. The CRSP stock price is -47.6% off its 52-week high price of $91.10 and 39.16% above the 52-week low of $37.55. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.24 million shares traded. The 3-month trading volume is 1.87 million shares.
CRISPR Therapeutics AG (NASDAQ:CRSP) trade information
Sporting -5.32% in the red today, the stock has traded in the red over the last five days, when the CRSP stock price touched $61.72 or saw a rise of 8.22%. Year-to-date, CRISPR Therapeutics AG shares have moved -1.41%, while the 5-day performance has seen it change -4.46%. Over the past 30 days, the shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have changed -19.66%. Short interest in the company has seen 14.72 million shares shorted with days to cover at 6.82.
CRISPR Therapeutics AG (CRSP) estimates and forecasts
Figures show that CRISPR Therapeutics AG shares have underperformed across the wider relevant industry. The company’s shares have gained 43.33% over the past 6 months, with this year growth rate of -221.65%, compared to 13.70% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are -110.40% and -55.10% for the next quarter. Revenue growth from the last financial year stood is estimated to be -70.60%.
16 analysts offering their estimates for the company have set an average revenue estimate of $17.91 million for the current quarter. 16 have an estimated revenue figure of $10.99 million for the next quarter concluding in Jun 2024. Year-ago sales stood $100 million and $70 million respectively for this quarter and the next, and analysts expect sales will shrink by -82.10% for the current quarter and -84.30% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 10.83% over the past 5 years.
CRSP Dividends
CRISPR Therapeutics AG is expected to release its next earnings report on February 21 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
CRISPR Therapeutics AG (NASDAQ:CRSP)’s Major holders
Insiders own 1.42% of the company shares, while shares held by institutions stand at 66.81% with a share float percentage of 67.78%. Investors are also buoyed by the number of investors in a company, with CRISPR Therapeutics AG having a total of 623 institutions that hold shares in the company. The top two institutional holders are ARK Investment Management, LLC with over 7.16 million shares worth more than $325.13 million. As of Sep 29, 2023, ARK Investment Management, LLC held 9.02% of shares outstanding.
The other major institutional holder is Capital International Investors, with the holding of over 6.07 million shares as of Jun 29, 2023. The firm’s total holdings are worth over $340.75 million and represent 7.64% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are ARK ETF Tr-ARK Innovation ETF and New Perspective Fund Inc. As of Sep 29, 2023, the former fund manager holds about 6.19% shares in the company for having 4.91 million shares of worth $223.04 million while later fund manager owns 3.55 million shares of worth $199.33 million as of Jun 29, 2023, which makes it owner of about 4.47% of company’s outstanding stock.
